Junctional tachycardia medical therapy: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Junctional tachycardia}} {{CMG}} ==Overview== ==Medical Therapy== *Treatment consists of supportive care or correction of the underlying disorder that triggered ..." |
No edit summary |
||
| Line 8: | Line 8: | ||
*Treatment consists of supportive care or correction of the underlying disorder that triggered the junctional automaticity. | *Treatment consists of supportive care or correction of the underlying disorder that triggered the junctional automaticity. | ||
*Treat symptomatic [[digitalis toxicity]] with [[atropine]] and [[digoxin immune Fab]] ([[Digibind]]) | *Treat symptomatic [[digitalis toxicity]] with [[atropine]] and [[digoxin immune Fab]] ([[Digibind]]) | ||
==References== | ==References== | ||
Latest revision as of 15:47, 21 August 2013
|
Junctional tachycardia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Junctional tachycardia medical therapy On the Web |
|
American Roentgen Ray Society Images of Junctional tachycardia medical therapy |
|
Risk calculators and risk factors for Junctional tachycardia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
- Treatment consists of supportive care or correction of the underlying disorder that triggered the junctional automaticity.
- Treat symptomatic digitalis toxicity with atropine and digoxin immune Fab (Digibind)